X
FATE icon

Xponance’s Fate Therapeutics FATE Stock Holding History

Xponance’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,821
Closed -$224K – 1177
2021
Q4 		$224K Buy
3,821
+15
+0.4% +$850 ﹤0.01% 1104
2021
Q3 		$226K Sell
3,806
-584
-13% -$45.8K ﹤0.01% 1096
2021
Q2 		$381K Buy
+4,390
New +$354K 0.01% 1008

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Xponance's FATE Position: Q1 2022 in Review

Xponance sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 3,821 shares — an estimated $224K sold.

Xponance first reported a position in FATE in Q2 2021 and held it in 3 quarters. The position peaked at $381K in Q2 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Xponance reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Xponance sold 3,821 Fate Therapeutics shares in Q1 2022, an estimated $224K.
  • Xponance first reported a position in Fate Therapeutics in Q2 2021 and held it in 3 quarters.
  • Xponance's Fate Therapeutics position peaked at $381K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Xponance's 13F filing for Q1 2022, filed 20 Apr 2022.